Organogenesis Holdings Inc. (ORGO) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Organogenesis Holdings Inc. (ORGO:NASDAQ), powered by AI.

Current Price
$2.40
P/E Ratio
8.2
Market Cap
304M
Sector
Healthcare
What is the Organogenesis Holdings Inc. stock price forecast?

Organogenesis Holdings Inc. is currently trading at $2.40. View real-time AI analysis on Alpha Lenz.

What is Organogenesis Holdings Inc. insider trading activity?

View the latest insider trading data for Organogenesis Holdings Inc. on Alpha Lenz.

What is Organogenesis Holdings Inc.'s P/E ratio?

Organogenesis Holdings Inc.'s P/E ratio is 8.2.

Organogenesis Holdings Inc.

NASDAQ · ORGO
$2.40-0.01(-0.41%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Organogenesis Holdings Inc.'s future dividend policy...
Alpha Chat Insight

Organogenesis Holdings Inc. trades at a P/E of 8.2 (undervalued) with solid ROE of 9.0%.

Ask for details

Company Overview

Organogenesis Holdings Inc. is a prominent entity in the biotechnology field, engaged in the development, manufacture, and services related to regenerative medicine products. The company's primary focus is on products that help solve complex medical conditions by harnessing the body's natural ability to repair and regenerate tissue. These products are particularly significant in the areas of advanced wound care and surgical and sports medicine. By offering bioactive and acellular biomaterials, Organogenesis plays a crucial role in speeding up the healing process for patients and enhancing clinical outcomes. Organogenesis Holdings Inc. operates its business through a comprehensive distribution network which provides its solutions to healthcare providers across the United States and internationally. The company's efforts in the regenerative medicine space have significant implications for sectors such as hospitals, clinics, and specialized centers dealing with wound care and surgical applications. By contributing to advancements in tissue repair, the firm's products hold a noteworthy position in the healthcare market, impacting both medical practices and patient care worldwide.

CEOMr. Gary S. Gillheeney Sr.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees869

Company Statistics

FY 2025

Profile

$304.17MMarket Cap
$563.03MRevenue
0.00Shares Out
869Employees

Margins

75.57%Gross
16.69%EBITDA
9.92%Operating
8.34%Pre-Tax
6.58%Net

Valuation

8.21P/E
0.70P/B
0.54EV/Sales
3.11EV/EBITDA
-12.44P/FCF

Growth (CAGR)

7.68%Rev 3Yr
10.73%Rev 5Yr
35.81%Op Inc 3Yr
15.91%Op Inc 5Yr
33.59%Net Inc 3Yr
16.53%Net Inc 5Yr

Returns

6.75%ROA
9.04%ROE
10.19%ROIC

Financial Health

$93.68MCash & Cash Equivalents
$71.13MNet Debt
37.98%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Organogenesis Holdings Inc. (ticker: ORGO) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 869 employees. Market cap is $304M.

The current price is $2.4 with a P/E ratio of 8.21x and P/B of 0.7x.

ROE is 9.04% and operating margin is 9.92%. Annual revenue is $563M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Organogenesis Holdings Inc. (ORGO) Stock Forecast 2026 $2.40 — Price, Financials & Analyst Targets | Alpha Lenz